Skip to main content

Table 1 Base-case values and ranges used in sensitivity analyses (± 30 %)

From: Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma

Parameters

Base estimate

Lower Limit- Upper Limit

Assumed distribution

Transition Probability

 PFS for sorafenib

0.1533

0.1073–0.1993

Beta

 PFS To PD for sorafenib

0.0627

0.044–0.082

Beta

 PD To death for sorafenib

0.1184

0.063–0.154

Beta

 PFS for SBRT

0.086

0.061–0.034

Beta

 PFS To PD for SBRT

0.109

0.076–0.142

Beta

 PD To death for SBRT

0.0399

0.028–0.052

Beta

Utility

 PFS for sorafenib

0.76

0.546–1.014

Beta

 PD for sorafenib

0.68

0.476–0.806

Beta

 PFS for SBRT

0.72

0.504–0.936

Beta

 PD for SBRT

0.63

0.441–0.819

Beta

Direct Medical Costs (US$ = 33 NT)

   

 cPFS for sorafenib

563365

394355–732375

Constant

 cPFS for SBRT

259056

181339–336773

Constant

 cPD for sorafenib

417528

292270–542786

Constant

 cPD for SBRT

417528

292270–542786

Constant

  1. Abbreviations: c cost, SBRT sterotactic body radiation therapy, PFS progression free survival, PD progression disease